Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2024-05-27 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
关于自愿披露PROTAC在研药物HP518在2024年美国临床肿瘤学会 (ASCO) 年会发布临床数据的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of clinical data for an investigational drug HP518 at the 2024 American Society of Clinical Oncology (ASCO) annual meeting. It contains detailed clinical trial data, safety and efficacy results, and risk warnings. The document is relatively short (1646 characters) and is an announcement of clinical data release rather than a full financial or regulatory report. It does not contain financial statements, audit information, or management changes. It is not a report publication announcement since it provides substantive clinical data and risk disclosures. The content fits best under a Regulatory Filings (RNS) category as it is a regulatory announcement about clinical trial data disclosure, not a financial or governance report.
2024-05-27 Chinese
关于高级管理人员离职暨核心技术人员调整的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the resignation of a senior management member and core technical personnel of the company. It details the departure of the Chief Medical Officer, the handover of responsibilities, and the impact on the company's operations and R&D capabilities. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to shareholder votes or capital changes. The content focuses on management changes and personnel adjustments at the senior level. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 2423 characters, which is consistent with a detailed announcement rather than a brief notice or report publication announcement.
2024-05-24 Chinese
中信证券股份有限公司关于海创药业股份有限公司核心技术人员离职的核查意见
Board/Management Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the departure of a core technical personnel at a pharmaceutical company. It includes specific information about the individual's role, patent involvement, confidentiality obligations, impact on the company, and measures taken. The document is not a financial report, earnings release, or regulatory filing but rather a specialized report related to management and personnel changes. It does not announce voting results, capital changes, or legal proceedings. The content focuses on management-level personnel changes and their impact on the company, fitting the category of Board/Management Information (MANG). The document length is 2465 characters, which is sufficient for a detailed report rather than a brief announcement. Therefore, the classification is MANG with high confidence.
2024-05-24 Chinese
关于参加2023年度科创板制药专场集体业绩说明会暨2024年第一季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the company's participation in an investor performance briefing session for the 2023 annual and 2024 first quarter results. It provides details about the meeting time, location, format (online interactive session), and how investors can participate and ask questions. It references that the company has already published the 2023 annual report and 2024 first quarter report on earlier dates. The document itself does not contain financial statements or detailed financial data but is an announcement of an upcoming investor presentation event related to those reports. Therefore, it fits the category of an Investor Presentation (IP) announcement rather than the actual report or earnings release.
2024-05-13 Chinese
北京君合（成都）律师事务所关于海创药业股份有限公司2023年年度股东大会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2023 Annual General Meeting (AGM) of the company. It details the legality of the AGM's convening, attendance, voting procedures, and results. The document includes specific references to the AGM, voting results, and compliance with company law and regulations. It does not contain the actual annual report or financial statements but focuses on the AGM process and validation. Therefore, this document fits the category of AGM Information (AGM-R). The document length is sufficient and contains detailed AGM-related content, not just an announcement or certification.
2024-05-10 Chinese
2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2023 年年度股东大会决议公告" which translates to "2023 Annual General Meeting Resolution Announcement." It details the date and location of the AGM, attendance, voting results on various proposals including the 2023 annual report, financial reports, profit distribution plan, and other corporate matters. The document includes voting percentages and confirms the legality and validity of the meeting and resolutions. There is no full financial report or detailed financial statements included, only the announcement of the resolutions passed at the AGM. The document length is 4613 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-05-10 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.